Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, HALO

Halozyme

$18.74

-0.46 (-2.40%)

05:30
12/12/19
12/12
05:30
12/12/19
05:30

Genentech says Phase III FeDeriCa study met primary endpoint

Genentech, a member of the Roche Group (RHHBY), announced new data from the Phase III FeDeriCa study which showed the investigational fixed-dose combination, or FDC, of Perjeta and Herceptin with hyaluronidase, administered by subcutaneous, or SC, injection in combination with intravenous chemotherapy, demonstrated non-inferior levels of Perjeta in the blood and comparable efficacy and safety to standard IV infusions of Perjeta plus Herceptin and chemotherapy in eligible people with HER2-positive early breast cancer, or EBC. The FeDeriCa study met its primary endpoint, with SC administration of the FDC showing non-inferior levels of Perjeta in the blood during a given dosing interval when compared to IV administration of Perjeta. The FDC of Perjeta and Herceptin is a new SC formulation that combines Perjeta and Herceptin with Halozyme Therapeutics' (HALO) Enhanze drug delivery technology.

RHHBY

Roche

$0.00

(0.00%)

HALO

Halozyme

$18.74

-0.46 (-2.40%)

  • 12

    Dec

  • 16

    Dec

RHHBY Roche
$0.00

(0.00%)

11/01/19
LEER
11/01/19
NO CHANGE
Target $26
LEER
Outperform
Dicerna price target raised to $26 from $22 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna Pharmaceuticals (DRNA) to $26 from $22 saying the terms for the company's partnership with Roche (RHHBY) to develop and commercialize DCR-HBVS are "quite favorable." Dicerna will receive a $200M upfront payment, up to $1.47B in potential milestones, and up to mid-teens royalties on future sales. The transaction is "meaningfully validating" for Dicerna's strategy for large population indications, Foroohar tells investors in a research note. With shares trading at an implied enterprise value "materially below" the pre-deal value, investors should begin to appreciate the scope of the potential partnership opportunities, says the analyst. He keeps an Outperform rating on Dicerna.
11/01/19
HCWC
11/01/19
NO CHANGE
Target $22
HCWC
Buy
Dicerna HBV deal earlier, on better terms than expected, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce affirmed his Buy rating on Dicerna Pharmaceuticals (DRNA) shares after the companpy announced a collaboration and licensing agreement with Roche (RHHBY) for the worldwide development and commercialization the company's lead asset for the treatment of hepatitis B virus, or HBV. While he has long anticipated "a large HBV deal," the collaboration with Roche is earlier, and with better economics, than Arce had expected, the analyst tells investors. He maintains a $22 price target on Dicerna shares.
11/14/19
WBLR
11/14/19
INITIATION
WBLR
Market Perform
William Blair says Ionis fairly valued on Spinraza headwinds
William Blair analyst Myles Minter initiated coverage of Ionis Pharmaceuticals with a Market Perform rating and $58 fair value estimate. Spinraza, which is marketed by Biogen (BIIB), generates about $2B in revenue per year and has revolutionized the treatment of spinal muscular atrophy, but its long-term growth potential faces headwinds, Minter tells investors in a research note. The analyst anticipates the recent approval of Novartis's (NVS) Zolgensma, an SMA gene therapy, will erode Spinraza's market share of new-start type-1 SMA patients. But more concerning, according to Minter, is the potential 2020 U.S. approval of Roche's (RHHBY) risdiplam, which he believes could erode Spinraza's total market share of type-2/3 patients given a more favorable oral route of delivery. The analyst sees Ionis shares as fairly valued at current levels given the near-term headwinds for its commercial franchise.
11/19/19
LEER
11/19/19
NO CHANGE
Target $30
LEER
Outperform
Dicerna price target raised to $30 from $26 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Dicerna (DRNA) to $30 from $26 and maintained an Outperform rating after the company announced a collaboration with Novo Nordisk (NVO) to develop candidates for liver-related cardiometabolic diseases. In a research note to investors, Foroohar says that while Dicerna's stock has traded up about 30% since the announcement of a partnership with Roche (RHHBY), it remains undervalued.
HALO Halozyme
$18.74

-0.46 (-2.40%)

07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
09/11/19
CANT
09/11/19
NO CHANGE
CANT
Overweight
Halozyme offers 'low-risk/high-reward' event in Q4, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on shares of Halozyme Therapeutics after a meeting with the company's CEO left him believing that a "clear read" will be seen with the HALO-301 trial in pancreatic cancer later in 2019. However, the analyst continues to see Halozyme share upside "almost irrespective" of the outcome of the Phase 3 trial in Q4. Investors appreciate the high risk in pancreatic cancer, says Duncan, who sees low expectations for Phase 3 success being priced into the current share price. The company's "growing" Enhanze franchise is the major driver of share value going forward post the HALO-301 readout, Duncan contends. He likes the design and rationale of the study, and therefore sees it as a "low-risk/high-reward" binary event.
11/05/19
LEHM
11/05/19
UPGRADE
Target $16
LEHM
Equal Weight
Halozyme upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Gena Wang upgraded Halozyme Therapeutics to Equal Weight from Underweight with a $16 price target.
11/05/19
LEHM
11/05/19
UPGRADE
Target $16
LEHM
Equal Weight
Halozyme upgraded to Equal Weight after HALO-301 failure at Barclays
Barclays analyst Gena Wang upgraded Halozyme Therapeutics to Equal Weight from Underweight with a price target of $16, down from $17. The analyst believes the HALO-301 failure removed a "major overhang." Strategic refocusing on the core business of Enhanze technology "would further unlock long-term value for the stock," Wang tells investors in a research note.

TODAY'S FREE FLY STORIES

T

AT&T

$38.36

0.33 (0.87%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

17:37
01/20/20
01/20
17:37
01/20/20
17:37
On The Fly
Box Office Battle: 'Bad Boys for Life' wins MLK Jr. weekend with $73M debut »

"Box Office Battle" is…

T

AT&T

$38.36

0.33 (0.87%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$72.48

-0.07 (-0.10%)

LGF.A

Lionsgate

$10.96

-0.32 (-2.84%)

LGF.B

Lionsgate

$10.32

-0.305 (-2.87%)

DIS

Disney

$144.25

-0.85 (-0.59%)

VIACA

ViacomCBS

$43.26

-0.855 (-1.94%)

VIAC

ViacomCBS

$39.48

-0.57 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

  • 04

    Feb

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

STIM

Neuronetics

$4.38

-0.01 (-0.23%)

17:00
01/20/20
01/20
17:00
01/20/20
17:00
Recommendations
Neuronetics analyst commentary  »

Correction in Neuronetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$60.76

-2.74 (-4.31%)

16:55
01/20/20
01/20
16:55
01/20/20
16:55
Recommendations
Tactile Systems analyst commentary  »

Lawsuit may drag out into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$48.49

0.16 (0.33%)

16:45
01/20/20
01/20
16:45
01/20/20
16:45
Earnings
Enterprise Financial reports Q4 EPS $1.09, consensus $1.09 »

Reports Q4 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

TGP

Teekay LNG

$14.73

-0.26 (-1.73%)

16:33
01/20/20
01/20
16:33
01/20/20
16:33
Hot Stocks
Teekay LNG Partners declares distribution of 19c per common unit »

Teekay GP, the general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WES

Western Midstream

$20.60

-0.55 (-2.60%)

16:31
01/20/20
01/20
16:31
01/20/20
16:31
Hot Stocks
Western Midstream announces Q4 2019 distribution »

Western Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CPG

Crescent Point Energy

$4.20

-0.08 (-1.87%)

16:29
01/20/20
01/20
16:29
01/20/20
16:29
Hot Stocks
Crescent Point closes sale of gas infrastructure assets »

Crescent Point announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHSCP

CHS Inc.

$28.85

0.13 (0.45%)

16:26
01/20/20
01/20
16:26
01/20/20
16:26
Hot Stocks
CHS Inc. names Olivia Nelligan as Chief Financial Officer »

CHS Inc. announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMAB

Genmab

$22.73

-0.13 (-0.57%)

, JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Hot Stocks
Genmab announces European Marketing Authorization for DARZALEX »

Genmab A/S (GMAB)…

GMAB

Genmab

$22.73

-0.13 (-0.57%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Mar

  • 17

    Mar

PRPO

Precipio

$2.09

-0.02 (-0.95%)

16:25
01/20/20
01/20
16:25
01/20/20
16:25
Conference/Events
Precipio to host shareholder update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

TILE

Interface

$17.37

0.23 (1.34%)

16:22
01/20/20
01/20
16:22
01/20/20
16:22
Hot Stocks
Interface names Dan Hendrix as President, CEO »

Interface announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.51

-0.26 (-1.14%)

16:19
01/20/20
01/20
16:19
01/20/20
16:19
Hot Stocks
Independent Bank announces 11% increase in quarterly cash dividend »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 19

    Feb

JAZZ

Jazz Pharmaceuticals

$151.00

-0.56 (-0.37%)

16:17
01/20/20
01/20
16:17
01/20/20
16:17
Hot Stocks
Jazz Pharmaceuticals receives EU Marketing Authorization for Sunosi »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AMRN

Amarin

$19.91

-0.15 (-0.75%)

16:13
01/20/20
01/20
16:13
01/20/20
16:13
Recommendations
Amarin analyst commentary  »

Amarin remains in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:09
01/20/20
01/20
16:09
01/20/20
16:09
Periodicals
Macron, Trump declare truce in digital tax dispute, Reuters reports »

French President Emmanuel…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

, HES

Hess Corp.

$69.87

-0.45 (-0.64%)

16:07
01/20/20
01/20
16:07
01/20/20
16:07
Periodicals
Guyana's first oil cargo to be refined by Exxon in the U.S., Reuters reports »

A vessel carrying…

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

HES

Hess Corp.

$69.87

-0.45 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

  • 23

    Mar

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:04
01/20/20
01/20
16:04
01/20/20
16:04
Periodicals
Tesla rebuffs U.S. safety recall petition, Reuters reports »

Tesla said there was no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

EADSY

Airbus

$0.00

(0.00%)

16:02
01/20/20
01/20
16:02
01/20/20
16:02
Periodicals
Airbus unit to offer product to help airlines with revenue risk, Reuters says »

A subsidiary of Airbus is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$318.66

3.33 (1.06%)

15:41
01/20/20
01/20
15:41
01/20/20
15:41
Periodicals
Apple CEO says global corporate tax system must be overhauled, Reuters reports »

Baking changes to global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:27
01/20/20
01/20
15:27
01/20/20
15:27
Periodicals
Alphabet calls for 'proportionate approach' to AI regulation, Reuters reports »

Sundar Pichai, the CEO of…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:24
01/20/20
01/20
15:24
01/20/20
15:24
Periodicals
Alphabet CEO backs temporary ban on facial-recognition, Reuters reports »

The EU's proposal…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

MSFT

Microsoft

$167.06

0.82 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

  • 25

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, AER

AerCap

$62.35

-0.18 (-0.29%)

15:10
01/20/20
01/20
15:10
01/20/20
15:10
Periodicals
AerCap CEO warns against panic discounts for Boeing 737 MAX, Reuters says »

Owners of Boeing's…

BA

Boeing

$324.11

-7.89 (-2.38%)

AER

AerCap

$62.35

-0.18 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 13

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

15:05
01/20/20
01/20
15:05
01/20/20
15:05
Periodicals
Aviation executive says Boeing should ditch 'MAX,' NY Post reports »

Steven Udvar-Hazy is the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BA

Boeing

$324.11

-7.89 (-2.38%)

14:08
01/20/20
01/20
14:08
01/20/20
14:08
Periodicals
Boeing close to securing $10B loan, Bloomberg reports »

Boeing is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CAE

CAE

$29.65

-0.14 (-0.47%)

14:05
01/20/20
01/20
14:05
01/20/20
14:05
Hot Stocks
CAE appoints Todd Probert as Group President, Defense & Security »

CAE announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.